Ptc Therapeutics Stock Current Valuation
| PTCT Stock | USD 57.14 0.51 0.90% |
Valuation analysis of PTC Therapeutics helps investors to measure PTC Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that PTC Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of PTC Therapeutics is based on 3 months time horizon. Increasing PTC Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
PTC Therapeutics' intrinsic value may or may not be the same as its current market price of 57.14, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 57.14 | Real 49.14 | Hype 57.14 | Naive 59.62 |
The intrinsic value of PTC Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence PTC Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of PTC Therapeutics helps investors to forecast how PTC stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of PTC Therapeutics more accurately as focusing exclusively on PTC Therapeutics' fundamentals will not take into account other important factors: PTC Therapeutics Company Current Valuation Analysis
PTC Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current PTC Therapeutics Current Valuation | 5.8 B |
Most of PTC Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PTC Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, PTC Therapeutics has a Current Valuation of 5.8 B. This is 59.64% lower than that of the Biotechnology sector and 24.81% higher than that of the Health Care industry. The current valuation for all United States stocks is 65.12% higher than that of the company.
PTC Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PTC Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PTC Therapeutics could also be used in its relative valuation, which is a method of valuing PTC Therapeutics by comparing valuation metrics of similar companies.PTC Therapeutics is currently under evaluation in current valuation category among its peers.
PTC Fundamentals
| Return On Equity | -77.4 | ||||
| Return On Asset | -0.0509 | ||||
| Profit Margin | (0.45) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 5.8 B | ||||
| Shares Outstanding | 78.87 M | ||||
| Shares Owned By Insiders | 2.45 % | ||||
| Shares Owned By Institutions | 99.99 % | ||||
| Number Of Shares Shorted | 3.7 M | ||||
| Price To Earning | (5.67) X | ||||
| Price To Book | 1,743 X | ||||
| Price To Sales | 5.59 X | ||||
| Revenue | 806.78 M | ||||
| Gross Profit | 214.9 M | ||||
| EBITDA | (120.46 M) | ||||
| Net Income | (363.3 M) | ||||
| Cash And Equivalents | 288.43 M | ||||
| Cash Per Share | 4.01 X | ||||
| Total Debt | 389.3 M | ||||
| Current Ratio | 1.23 X | ||||
| Book Value Per Share | (14.13) X | ||||
| Cash Flow From Operations | (107.69 M) | ||||
| Short Ratio | 4.91 X | ||||
| Earnings Per Share | (4.77) X | ||||
| Price To Earnings To Growth | 0.81 X | ||||
| Target Price | 64.93 | ||||
| Number Of Employees | 939 | ||||
| Beta | 0.66 | ||||
| Market Capitalization | 4.51 B | ||||
| Total Asset | 1.71 B | ||||
| Retained Earnings | (3.65 B) | ||||
| Working Capital | 784.55 M | ||||
| Current Asset | 355.95 M | ||||
| Current Liabilities | 45.39 M | ||||
| Net Asset | 1.71 B |
About PTC Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PTC Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PTC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PTC Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for PTC Stock Analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.